A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

ClinicalTrials.gov ID: NCT02500407

Public ClinicalTrials.gov record NCT02500407. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Study identification

NCT ID: NCT02500407
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 713 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 15, 2015 (Actual)
Primary completion: May 21, 2024 (Actual)
Completion: Sep 1, 2025 (Actual)
Last update posted: Sep 12, 2025

2015 – 2025

United States locations

U.S. sites: 12
U.S. states: 8
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of California San Diego Moores Cancer Center	La Jolla	California	92093-0698	—
Sansum Medical Clinic, Inc.	Santa Barbara	California	93105	—
Rocky Mountain Cancer Center	Denver	Colorado	80218	—
Yale University School Of Medicine	New Haven	Connecticut	06510	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Memorial Sloan Kettering Bergen	Montvale	New Jersey	07645	—
Memorial Sloan Kettering Cancer Center - Commack	Commack	New York	11725	—
Memorial Sloan Kettering Cancer Center at Westchester	Harrison	New York	10604	—
New York Uni Medical Center	New York	New York	10016	—
Willamette Valley Cancer Insitute and Research Center	Springfield	Oregon	97477	—
University of Pennsylvania	Philadelphia	Pennsylvania	19103	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02500407, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 12, 2025 · Synced Nov 7, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02500407 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →